Peripheral blood stem cell support does not accelerate haemopoietic recovery from miniBEAM chemotherapy

Bone Marrow Transplantation

Volumn 18, Issue 3, 1996, Pages 507-511

  Fielding, A K ^a,b   Goldstone, A H ^a   Sullivan, A M ^a   Watts, M J ^a   Jamieson, E ^a   Linch, D C ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

MiniBEAM; PBSC

Indexed keywords

ANTIBIOTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FEVER; HEMATOPOIESIS; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; PATIENT CARE; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CYTARABINE; ETOPOSIDE; FEMALE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA; MALE; MELPHALAN; MIDDLE AGED;

EID: 0029792764     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Philip T, Gugliemi C, Cauvin F et al. The PARMA international randomised prospective study in relapsed non-Hodgkin lymphoma: first results of the final analysis. Bone Marrow Transplant 1995; 15 (Suppl. 2): S155.
2. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051-1054.
3. Rappoport AP, Rowe JM, Kouides PA et al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. J Clin Oncol 1993; 11: 2352-2361.
4. Fielding AK, Pearce RM, Taghipour G et al. Autologous bone marrow transplantation for lymphoma: a 15 year European Bone Marrow Transplant Registry experience of 3325 patients. Blood 1994; 84 (Suppl. 1): 536a.
5. Chopra R, McMillan AK, Linch DC et al. The place of high dose BEAM therapy and autologous bone marrow transplantation in poor risk Hodgkin's disease, a single centre study of 155 patients. Blood 1993; 5: 1137-1145
6. Gribben JG, Goldstone AH, Linch DC et al. Effectiveness of high dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who are still sensitive to conventional-dose therapy. J Clin Oncol 1989; 7: 1621-1629
7. Cabanillas F, Hagemeister FB, McLaughlin P et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 1987; 5: 407-412.
8. Velasquez W, McLaughlin P, Tucker S et al. ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994; 12: 1169-1176.
9. Velasquez WS, Cabanillas F, Salvador P et al. Effective salvage therapy for lymphoma with cisplatin in combination with high dose AraC and dexamethasone (DHAP). Blood 1988; 71: 117-122.
10. Chopra R, Linch DC, McMillan AK et al. MiniBEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease. Br J Haematol 1992; 83: 197-202.
11. Jones HM, Jones SA, Watts MJ et al. Development of a simplified single apheresis approach for peripheral blood progenitor cell transplantation in previously treated patients with lymphoma. J Clin Oncol 1994; 12: 1693-1702.
12. Watts MJ, Jones HM, Sullivan AM et al. Accessory cells do not contribute to G-CSF or IL-6 production nor to rapid haematological recovery following peripheral stem cell transplantation. Br J Haematol 1995; 91: 767-772.
13. 2 and G-CSF. Blood 1995; 86 (Suppl. 1 ): 408a.